Core Viewpoint - The company Yiming Pharmaceutical-B (01541.HK) has received approval from the National Medical Products Administration for clinical trials of IMM01 (Tida-pasip), aimed at treating atherosclerosis [1] Group 1: Product Information - The core product IMM01 (Tida-pasip) is an innovative targeted CD47 molecule and is the first SIRPα-Fc fusion protein to enter clinical stages in China [1] - IMM01 (Tida-pasip) utilizes a dual mechanism to activate macrophages by blocking the "don't eat me" signal through interference with the CD47/SIRPα interaction and delivering the "eat me" signal via Fc-gamma (Fcγ) receptor activation [1] - The CD47 binding domain of IMM01 (Tida-pasip) has been specially modified to avoid binding with human red blood cells (RBCs), demonstrating good safety and macrophage activation capabilities [1] Group 2: Regulatory Approvals - The combination of IMM01 (Tida-pasip) with Azacitidine for frontline treatment of Chronic Myelomonocytic Leukemia (CMML) received orphan drug designation from the U.S. Food and Drug Administration (FDA) in November 2023 [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration of China for clinical trials of IMM01 (Tida-pacisib) for the treatment of atherosclerosis, marking a significant milestone in its product development [1] Group 1: Product Development - IMM01 (Tida-pacisib) is an innovative targeted CD47 molecule and the first SIRPα-Fc fusion protein to enter clinical stages in China [1] - The product utilizes a dual mechanism to activate macrophages by blocking the "don't eat me" signal and delivering the "eat me" signal through Fc-gamma receptors [1] - The CD47 binding domain of IMM01 has been specially modified to avoid binding with human red blood cells, enhancing its safety profile [1] Group 2: Regulatory Approvals - IMM01 (Tida-pacisib) has been granted orphan drug designation by the U.S. Food and Drug Administration for first-line treatment of Chronic Myelomonocytic Leukemia (CMML) in November 2023 [1] Group 3: Intellectual Property - The company holds global intellectual property and commercialization rights for IMM01 (Tida-pacisib), with a patent family that includes granted patents in China, the United States, Japan, and the European Union [2]

Core Viewpoint - The company Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Ankang, received a notice of acceptance for the production registration application of Adalimumab injection from the National Medical Products Administration, indicating progress in the development of a biosimilar drug for various immune diseases [1] Group 1 - The drug Adalimumab is intended for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and other immune-related diseases [1] - As of the announcement date, eight other companies in China have already received approval for their Adalimumab injections [1] - The acceptance notice for the drug will not impact the company's recent performance, as the timing and outcome of the registration approval remain uncertain [1]

心玮医疗-B(06609)发布公告，于2026年1月12日，该公司斥资243.32万港元回购4万股股份，每股回购价 格为59.8-62.2港元。 ...

Group 1 - The core viewpoint of the news is that Zhixiang Jintai (688443.SH) is currently experiencing a decline in stock price, with a closing price of 31.95 yuan and a drop of 1.51%, indicating it is in a state of loss since its IPO [1] - Zhixiang Jintai was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on June 20, 2023, with a public offering of 91.68 million shares at an issue price of 37.88 yuan per share [1] - The total amount raised from the IPO was 347.28 million yuan, with a net amount of 329.14 million yuan after deducting issuance costs, which was 68.86 million yuan less than the originally planned amount of 398 million yuan [1] Group 2 - Zhixiang Jintai has reported losses for four consecutive years and three quarters, with net profits attributable to shareholders of -322 million yuan in 2021, -576 million yuan in 2022, -801 million yuan in 2023, and -797 million yuan in 2024 [2] - For the first three quarters of 2025, Zhixiang Jintai achieved an operating income of 20.8 million yuan, a significant increase of 1,562.05%, but still reported a net loss attributable to shareholders of -333 million yuan [2] - The net cash flow from operating activities for the company was -261 million yuan [2]

Group 1 - The core viewpoint of the article highlights a surge in IPO activity on the Hong Kong Stock Exchange (HKEX) at the beginning of 2026, driven by a wave of hard-tech companies seeking funding amidst cash flow challenges [2][4]. - Notable IPOs include companies like Wallen Technology, which saw a first-day surge of 94.59%, and several others in the AI and biotech sectors listing within a short timeframe [2][3]. - The article discusses the financial pressures faced by these companies, with significant losses reported in 2025, such as Wallen's loss of 1.6 billion and Zhipu's loss of 2.36 billion, highlighting the urgent need for capital [8][6]. Group 2 - The article explains that the relatively lower listing requirements on HKEX compared to other exchanges, such as the STAR Market and the ChiNext, make it an attractive option for startups [10][11]. - The presence of foreign investment and the ability to navigate complex ownership structures, such as VIE, further incentivize companies to choose HKEX for their IPOs [13][12]. - The article also notes that the HKEX is becoming a strategic battleground in the US-China tech and capital competition, with a significant portion of global dollar liquidity being redirected to Hong Kong [23][24]. Group 3 - The liquidity premium in the biotech sector is emphasized, as HKEX allows companies without commercial revenue to list, which is more favorable compared to A-share requirements [15][22]. - The article illustrates how foreign funds view business development (BD) differently, focusing on the potential for overseas licensing deals rather than just domestic sales, which influences valuation positively [21][20]. - The influx of quality assets and growth potential in HKEX is expected to enhance liquidity and attract more international capital, suggesting a bullish outlook for the Hong Kong market in 2026 [29][28].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 – 1 – 本集團擁有IMM01（替達派西普）的全球知識產權及商業化權利。截至本公告日 期，就IMM01（替達派西普）而言，本集團擁有一個專利家族，其中包括在中國、 美國、日本及歐盟的已授權專利。 根據香港聯合交易所有限公司證券上市規則第18A.05條的警示聲明：本公司無 法保證能夠成功開發或最終上市銷售IMM01（替達派西普）。本公司股東及潛在 投資者在買賣本公司股份時應謹慎行事。 承董事會命 宜明昂科生物醫藥技術（上海）股份有限公司 自願公告 IMM01（替達派西普）獲國家藥監局批准進行 動脈粥樣硬化治療的臨床試驗 本公告由宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」，連同其附屬 公司統稱「本集 ...

Core Viewpoint - The company has submitted an application for overseas public offering and listing to the Hong Kong Stock Exchange on November 25, 2025, and has published the application materials on the same day [1] Group 1 - The application materials for the public offering have been accepted by the China Securities Regulatory Commission [1] - The issuance and listing are subject to approval, authorization, or filing by relevant regulatory agencies and stock exchanges, indicating uncertainty in the process [1] - The company will disclose updates on the progress of the application in a timely manner [1]

Group 1: IPO Highlights - Aktis Oncology led the week with a large IPO, raising $318 million at a valuation of $1 billion, focusing on α-radiopharmaceuticals for solid tumors [1] - Buda Juice completed its IPO at the lower end of its price range, raising $20 million with a market cap of $95 million, emphasizing its "super fresh" juice category [2] - Atlas Critical Minerals also completed its IPO at the lower end, raising $10 million with a market cap of $40 million, focusing on mineral exploration in Brazil [2] Group 2: SPAC Activity - Five SPACs completed their IPOs, including Lafayette Digital Acquisition and Bleichroeder Acquisition II, each raising $250 million, targeting financial services and technology sectors [3] - Other SPACs like Art Technology Acquisition and Soren Acquisition raised $220 million and $150 million respectively, focusing on technology and healthcare [3] Group 3: Upcoming IPO Filings - Six companies filed for IPOs, including Brazilian digital bank PicS seeking $500 million and discount furniture retailer Bobs Discount Furniture aiming for $400 million [5] - Other notable filings include Forgent Power Solutions for $200 million and Eikon Therapeutics for $100 million, both in the healthcare sector [5] Group 4: Market Outlook - The IPO market is expected to be quiet in the upcoming week after the recent large IPO, with smaller issuers potentially joining the market [6] - Several large companies that have submitted IPO applications remain eligible to go public soon, including EquipmentShare.com and Motive Technologies [7]

Core Viewpoint - Lepu Biopharma-B (02157) experienced a significant stock increase, rising over 6% in late trading, with a current price of HKD 5.64 and a trading volume of HKD 71.31 million [1] Group 1: Clinical Trial Developments - CG Oncology is set to announce the primary data from the PIVOT-006 Phase 3 clinical trial evaluating the monotherapy of cretostimogene for high-risk non-muscle invasive bladder cancer in the first half of 2026, which is nearly one year ahead of the original schedule due to a much faster-than-expected enrollment rate [1] - Lepu Biopharma holds the rights to CG0070 injection (Cretostimogene Grenadenorepvec) in Greater China and is actively advancing clinical progress domestically while CG Oncology achieves clinical breakthroughs abroad [1] Group 2: Product Synergy - Lepu Biopharma possesses an already marketed PD-1 antibody, Putilizumab, which can complement the treatment of NMIBC when combined with cretostimogene, potentially enhancing therapeutic efficacy [1]